Semustine

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Semustine is a drug catalogued in DrugCentral. DrugCentral lists 1 molecular target, including ADRA2A.

• Molecular targets: ADRA2A (1 listed in DrugCentral).
• ATC code: L01AD03 (Nitrosoureas).
• Molecular formula: C10H18ClN3O2; molecular weight 247.72 g/mol.

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 5.74

ATC classification

ATC code	Therapeutic hierarchy
L01AD03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ALKYLATING AGENTS › Nitrosoureas

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Cystitis haemorrhagic	90.4

Chemical structure

• Molecular formula: C₁₀H₁₈ClN₃O₂
• Molecular weight: 247.72 g/mol
• CAS number: 13909-09-6
• InChIKey: FVLVBPDQNARYJU-XAHDHGMMSA-N
• PubChem CID: 5198

C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Semustine work?

Its molecular targets in DrugCentral include ADRA2A.

What is the chemical formula of Semustine?

Semustine has the molecular formula C10H18ClN3O2 and a molecular weight of 247.72 g/mol.

Sources

• DrugCentral drug card 4704 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL12948 — compound record and bioactivity
• PubChem CID 5198 — chemical identifiers
• DrugBank DB13647 — drug record
• FDA UNII 6YY7T1T567 — substance identity
• UniProt P08913 (ADRA2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.